Video
Reduced Incidence of ICANS and CRS After 2 Weeks Post-CAR T Supports Shortened Monitoring Period in DLBCL
Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL
Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups
Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma
CAR T-Cell Therapy Selection in Follicular Lymphoma Requires Careful Consideration
Epcoritamab Shines in Third-Line Follicular Lymphoma With the Potential to Move into Earlier Lines
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
